Professional Education

  • Doctor of Philosophy, University of Miami, Industrial Engineering (2017)
  • Master of Science, University of Tehran, Industrial Engineering (2013)
  • Bachelor of Science, Sharif University of Technology, Industrial and System Engineering (2011)

All Publications

  • A comparative modeling analysis of risk-based lung cancer screening strategies. Journal of the National Cancer Institute Ten Haaf, K., Bastani, M., Cao, P., Jeon, J., Toumazis, I., Han, S. S., Plevritis, S. K., Blom, E. F., Kong, C. Y., Tammemägi, M. C., Feuer, E. J., Meza, R., de Koning, H. J. 2019


    Risk-prediction models have been proposed to select individuals for lung cancer screening. However, their long-term effects are uncertain. This study evaluates long-term benefits and harms of risk-based screening compared to current United States Preventive Services Task Force (USPSTF) recommendations.Four independent natural-history models performed a comparative modeling study evaluating long-term benefits and harms of selecting individuals for lung cancer screening through risk-prediction models. 363 risk-based screening strategies varying by screening starting and stopping age, risk-prediction model used for eligibility (Bach, PLCOm2012, LCDRAT), and risk-threshold were evaluated for a 1950 U.S. birth-cohort. Among the evaluated outcomes were percentage of individuals ever screened, screens required, lung cancer deaths averted, life-years gained and overdiagnosis.Risk-based screening strategies requiring similar screens among individuals aged 55-80 as the USPSTF-criteria (corresponding risk-thresholds: Bach: 2.8%, PLCOm2012: 1.7%, LCDRAT: 1.7%) averted considerably more lung cancer deaths (Bach: 693, PLCOm2012: 698, LCDRAT: 696, USPSTF: 613). However, life-years gained were only modestly higher (Bach: 8,660, PLCOm2012: 8,862, LCDRAT, 8,631,USPSTF: 8,590) and risk-based strategies had more overdiagnosis (Bach: 149, PLCOm2012: 147, LCDRAT: 150, USPSTF: 115). Sensitivity analyses suggests excluding individuals with limited life-expectancies (<5 years) from screening retains the life-years gained by risk-based screening, while reducing overdiagnosis by > 65.3%.Risk-based lung cancer screening strategies prevent considerably more lung cancer deaths than current recommendations. However, they yield modest additional life-years and increased overdiagnosis due to predominantly selecting older individuals. Efficient implementation of risk-based lung cancer screening requires careful consideration of life-expectancy for determining optimal individual stopping ages.

    View details for DOI 10.1093/jnci/djz164

    View details for PubMedID 31566216

  • Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Annals of internal medicine Criss, S. D., Cao, P., Bastani, M., Ten Haaf, K., Chen, Y., Sheehan, D. F., Blom, E. F., Toumazis, I., Jeon, J., de Koning, H. J., Plevritis, S. K., Meza, R., Kong, C. Y. 2019


    Recommendations vary regarding the maximum age at which to stop lung cancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74 years according to the National Lung Screening Trial (NLST).To compare the cost-effectiveness of different stopping ages for lung cancer screening.By using shared inputs for smoking behavior, costs, and quality of life, 4 independently developed microsimulation models evaluated the health and cost outcomes of annual lung cancer screening with low-dose computed tomography (LDCT).The NLST; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SEER (Surveillance, Epidemiology, and End Results) program; Nurses' Health Study and Health Professionals Follow-up Study; and U.S. Smoking History Generator.Current, former, and never-smokers aged 45 years from the 1960 U.S. birth cohort.45 years.Health care sector.Annual LDCT according to NLST, CMS, and USPSTF criteria.Incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $100 000 per quality-adjusted life-year (QALY).The 4 models showed that the NLST, CMS, and USPSTF screening strategies were cost-effective, with ICERs averaging $49 200, $68 600, and $96 700 per QALY, respectively. Increasing the age at which to stop screening resulted in a greater reduction in mortality but also led to higher costs and overdiagnosis rates.Probabilistic sensitivity analysis showed that the NLST and CMS strategies had higher probabilities of being cost-effective (98% and 77%, respectively) than the USPSTF strategy (52%).Scenarios assumed 100% screening adherence, and models extrapolated beyond clinical trial data.All 3 sets of lung cancer screening criteria represent cost-effective programs. Despite underlying uncertainty, the NLST and CMS screening strategies have high probabilities of being cost-effective.CISNET (Cancer Intervention and Surveillance Modeling Network) Lung Group, National Cancer Institute.

    View details for DOI 10.7326/M19-0322

    View details for PubMedID 31683314

  • An evolutionary simulation optimization framework for interruptible load management in the smart grid SUSTAINABLE CITIES AND SOCIETY Bastani, M., Thanos, A. E., Damgacioglu, H., Celik, N., Chen, C. 2018; 41: 802–9